Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 6/20 | 0.48 |
| ▸ | TPH1 | P17752 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104029 | 1.00 | SLC7A5 (0.48) | SLC7A5TRPA1DPP4TPH1ALPI | |
| SCHEMBL4674111 | 1.00 | SLC7A5 (0.48) | SLC7A5TRPA1DPP4TPH1ALPI | |
| SCHEMBL8122117 | 0.84 | SLC7A5 (0.48) | SLC7A5TRPA1DPP4TPH1ALPI | |
| SCHEMBL29825250 | 0.84 | SLC7A5 (0.69) | SLC7A5TPH1ALPIPKMPTGS1 | |
| SCHEMBL27221201 | 0.84 | SLC7A5 (0.69) | SLC7A5TPH1ALPIPKMPTGS1 | |
| SCHEMBL23320242 | 0.84 | SLC7A5 (0.69) | SLC7A5TPH1ALPIPKMPTGS1 | |
| SCHEMBL12028778 | 0.84 | SLC7A5 (0.48) | SLC7A5TRPA1DPP4TPH1ALPI | |
| SCHEMBL72793 | 0.84 | SLC7A5 (0.69) | SLC7A5TPH1ALPIPKMPTGS1 | |
| SCHEMBL10348775 | 0.84 | SLC7A5 (0.48) | SLC7A5TRPA1DPP4TPH1ALPI | |
| SCHEMBL44071 | 0.84 | SLC7A5 (0.69) | SLC7A5TPH1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-8466107-B2 | Fibrin-binding peptides and conjugates thereof | BRACCO IMAGING SPA (IT) | 2013-06-18 | — | — | US | disclosed |
| US-20120328512-A1 | Fibrin-Binding Peptides and Conjugates Thereof | BRACCO IMAGING S.P.A. (IT) | 2012-12-27 | — | — | US | disclosed |
| US-8278274-B2 | Fibrin-binding peptides and conjugates thereof | BRACCO IMAGING SPA (IT) | 2012-10-02 | — | — | US | disclosed |
| US-20100158814-A1 | Fibrin-Binding Peptides and Conjugates Thereof | BRACCO IMAGING S.P.A. (IT) | 2010-06-24 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328512-A1 | Fibrin-Binding Peptides and Conjugates Thereof | FGB, F13B, F13A1 | SLC7A5 2022/4885TRPA1 4877/4885DPP4 1718/4885 |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | SLC7A5 3660/4885TRPA1 4782/4885DPP4 201/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | SLC7A5 232/4885TRPA1 4265/4885DPP4 93/4885 |
| US-20100158814-A1 | Fibrin-Binding Peptides and Conjugates Thereof | FGB, F13B, F13A1 | SLC7A5 2049/4885TRPA1 4877/4885DPP4 1760/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | SLC7A5 232/4885TRPA1 4265/4885DPP4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.